Macquarie Group Ltd. Purchases Shares of 150,483 UiPath Inc. (NYSE:PATH)

Macquarie Group Ltd. purchased a new stake in shares of UiPath Inc. (NYSE:PATH) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 150,483 shares of the healthcare company’s stock, valued at approximately $2,642,000.

Other hedge funds have also modified their holdings of the company. Creative Planning raised its position in shares of UiPath by 7.0% in the 2nd quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock valued at $185,000 after purchasing an additional 666 shares during the last quarter. Voya Investment Management LLC raised its position in shares of UiPath by 1.2% in the 4th quarter. Voya Investment Management LLC now owns 58,567 shares of the healthcare company’s stock valued at $744,000 after purchasing an additional 719 shares during the last quarter. SRS Capital Advisors Inc. raised its position in shares of UiPath by 20.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 5,208 shares of the healthcare company’s stock valued at $66,000 after purchasing an additional 884 shares during the last quarter. Daiwa Securities Group Inc. raised its position in shares of UiPath by 24.4% in the 1st quarter. Daiwa Securities Group Inc. now owns 5,705 shares of the healthcare company’s stock valued at $100,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its position in shares of UiPath by 0.7% in the 1st quarter. Treasurer of the State of North Carolina now owns 164,798 shares of the healthcare company’s stock valued at $2,894,000 after purchasing an additional 1,170 shares during the last quarter. 59.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at UiPath

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $18.44, for a total value of $737,600.00. Following the completion of the transaction, the chief financial officer now directly owns 1,384,047 shares of the company’s stock, valued at approximately $25,521,826.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Rich Wong sold 56,549 shares of the business’s stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $17.97, for a total transaction of $1,016,185.53. Following the completion of the transaction, the director now directly owns 879,693 shares of the company’s stock, valued at $15,808,083.21. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $18.44, for a total value of $737,600.00. Following the transaction, the chief financial officer now directly owns 1,384,047 shares of the company’s stock, valued at $25,521,826.68. The disclosure for this sale can be found here. Insiders sold a total of 136,549 shares of company stock valued at $2,374,586 in the last three months. 31.03% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

PATH has been the topic of several research reports. Royal Bank of Canada increased their price target on shares of UiPath from $18.00 to $19.00 and gave the stock a “sector perform” rating in a report on Thursday, September 7th. BMO Capital Markets raised their price objective on shares of UiPath from $18.00 to $19.00 and gave the stock a “market perform” rating in a research note on Thursday, September 7th. Needham & Company LLC reissued a “buy” rating and issued a $20.00 price target on shares of UiPath in a research note on Thursday, September 7th. DA Davidson lifted their price target on shares of UiPath from $16.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, September 7th. Finally, Macquarie lifted their price target on shares of UiPath from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Thursday, September 7th. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.84.

UiPath Stock Down 0.8 %

NYSE PATH opened at $17.42 on Tuesday. UiPath Inc. has a 52 week low of $10.40 and a 52 week high of $19.94. The business’s fifty day simple moving average is $16.64 and its 200-day simple moving average is $16.27. The firm has a market cap of $9.78 billion, a PE ratio of -54.44 and a beta of 0.69.

UiPath (NYSE:PATH) last issued its quarterly earnings data on Wednesday, September 6th. The healthcare company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. The firm had revenue of $287.31 million for the quarter, compared to analyst estimates of $281.48 million. UiPath had a negative net margin of 15.47% and a negative return on equity of 7.49%. UiPath’s revenue was up 18.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.18) EPS. Research analysts expect that UiPath Inc. will post -0.28 EPS for the current year.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.